Actinium Pharmaceuticals (ATNM) : During the past 4 weeks, traders have been relatively bearish on Actinium Pharmaceuticals (ATNM), hence the stock is down -20.16% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -24.71% relative to the S&P 500. The 4-week change in the price of the stock is -20.59% and the stock has fallen -24.58% in the past 1 week.
The stock has recorded a 20-day Moving Average of 21.24% and the 50-Day Moving Average is 20.99%.The 200 Day SMA reached 30.12%
Actinium Pharmaceuticals (NYSEMKT:ATNM): After opening at $1.34, the stock dipped to an intraday low of $1.29 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $1.37 and the buying power remained strong till the end. The stock closed at $1.35 for the day, a gain of 1.50% for the day session. The total traded volume was 1,257,495. The stocks close on the previous trading day was $1.35.
Actinium Pharmaceuticals (ATNM) : Currently there are 3 street experts covering Actinium Pharmaceuticals (ATNM) stock. The most bullish and bearish price target for the stock is $9 and $5 respectively for the short term. The average price target of all the analysts comes to $7.33. The estimated standard deviation from the target is $2.08.
Actinium Pharmaceuticals, Inc. (Actinium) is a biopharmaceutical company engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The Companys products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). As of December 31, 2014, Actiniums Actimab-A was in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. As of December 31, 2014, the Company had four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. As of December 31, 2014, BC8-Y-90 and BC8-SA were in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center (FHCRC).